Vertaling van "2009 annual report and includes " (Nederlands → Frans) :

See note 20 in the Group’s Consolidated Financial Statements in the 2009 Annual Report for a summary of major legal proceedings. The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and includes information as of the 2009 fourth quarter:
Pour un résumé des litiges majeurs, prière de consulter la note 20 des Comptes consolidés du Groupe figurant dans le rapport annuel 2009.La liste suivante, non exhaustive, passe en revue quelquesuns des cas cités dans le Rapport annuel 2009 et contient les informations disponibles au quatrième trimestre 2009.

The following is a non-exhaustive list relating to some cases reported in the 2008 Annual Report and includes information as of the first nine months in 2009:
Non exhaustive, la liste suivante passe en revue quelques-uns des cas cités dans le Rapport annuel 2008 et contient les informations disponibles au cours des neuf premiers mois de 2009.

The following is a non-exhaustive list relating to some cases reported in the 2008 Annual Report and includes information as of the 2009 first half:
Non exhaustive, la liste suivante passe en revue quelques-uns des cas cités dans le Rapport annuel 2008 et contient les informations disponibles au premier semestre 2009.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

In particular, as discussed in notes 4 and 11 of the 2009 Annual Report, investments in associated companies and intangible assets (including goodwill and acquired In-Process Research & Development projects) are reviewed for impairment at least annually, or whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme l’indiquent également les notes 4 et 11 du Rapport annuel 2009, les investissements dans les entreprises associées et les immobilisations incorporelles (y compris le goodwill et les projets acquis qui sont intégrés dans le processus de recherche et développement) font l’objet d’un test de dépréciation au moins une fois par an ou dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.

The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and other cases of significance, and includes information as of October 21, 2010:
La liste suivante, non exhaustive, passe en revue quelques-uns des cas cités dans le Rapport annuel 2009 ainsi que d’autres cas importants et contient les informations disponibles au 21 octobre 2010.

The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and other cases of significance, and includes information as of July 15, 2010:
La liste suivante, non exhaustive, passe en revue quelques-uns des cas cités dans le Rapport annuel 2009 ainsi que d’autres cas importants et contient les informations disponibles au 15 juillet 2010.

The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and includes information as of April 19, 2010:
La liste suivante, non exhaustive, passe en revue quelques-uns des cas cités dans le Rapport annuel 2009 et contient les informations disponibles au 19 avril 2010.

NB De technische definities zijn opgenomen in deel IV van het jaarverslag 2009 van het RIZIV. [http ...]
N.B. Les définitions techniques se trouvent dans le rapport annuel 2009 de l’INAMI, partie IV. [http ...]

De meest recente officiële openbare Europese epidemiologische gegevens dateren van oktober 2009 (ECDC Annual Epidemiological Report on Communicable Diseases in the European Union).
Les données épidémiologiques européennes officielles publiques les plus récentes datent de 2009 (European Centre for Disease Prevention and Control (ECDC) Annual Epidemiological Report on Communicable Diseases in the European Union).